The Study of Decarbonizing Pharmaceutical Plants in Southeast Asia, posted on ISPE’s “Pharmaceutical Engineering.”

The ISPE bi-monthly magazine ‘Pharmaceutical Engineering’ (November/December 2024) has been published with an article contributed by our employees, Mr. Goto, Mr. Tahara, Mr. Inoue and Dr. Hasunuma. The article introduces our efforts to reduce carbon emissions while identifying hazards and assessing risks from a GMP perspective in order to decarbonize pharmaceutical plants in Southeast Asia.

Summary of the article

Title	“Decarbonizing Pharmaceutical Manufacturing Facilities for Drug Products’ Carbon Footprint Reduction”
Authors	Mr. Koichi GOTO (MSc), Senior General Manager of the Overseas Strategy Office at CM Plus Corporation, Mr. Shigehiro TAHARA, Senior advisor about International Pharmaceutical Manufacturing Facility Engineering of CM Plus Corporation, Mr. Yoshiyuki Inoue, Corporate Officer at CM Plus Singapore Dr. Hideki Hasunuma, HVAC and Carbon Neutral Engineer at CM Plus Corporation.
Abstracts	Reducing pharmaceutical’s carbon footprint has become a management responsibility. This paper introduces some of the key points, actual methods, and practical examples of our implementation to reduce carbon emissions from the pharmaceutical manufacturing facilities in Southeast Asia.In general drug production facilities, a hazard identification and risk assessment from a GMP perspective should always be performed on the proposed energy efficiency improvements identified from an engineering perspective, and the necessary actions should be considered. In some situations, it is possible that a proposed improvement may not be effective or feasible. Therefore, there are considerable hurdles to reduce carbon emission from drug manufacturing plants compared to general facilities. As an example, we will describe our approach for the decarbonization at an operational pharmaceutical manufacturing facility in Southeast Asia, with key steps along the way. The paper also includes a note on the sustainability aspects of the SDGs (Sustainable Development Goals). Carbon footprint reduction plan also requires a consideration of the manufacturing facility’s life cycle. We hope this paper will help to further reduce the carbon footprint of pharmaceutical manufacturing processes.

◆The full document can be accessed here: ‘Pharmaceutical Engineering’ (November/December 2024) : “Decarbonizing Pharmaceutical Manufacturing Facilities for Drug Products’ Carbon Footprint Reduction”
https://ispe.org/pharmaceutical-engineering/november-december-2024/decarbonizing-pharmaceutical-manufacturing
 

◆ISPE magazine ‘Pharmaceutical Engineering’

‘Pharmaceutical Engineering’ is a technical magazine published by the International Society for Pharmaceutical Engineering (ISPE). ISPE is a non-profit educational volunteer organization for the manufacturing of life sciences, etc., with 22,000 members in 90 countries around the world, and was established in the United States in 1980. publishes a technical journal for ISPE members engaged in the research, development and manufacturing of pharmaceuticals and medical devices once every two months.All technical content is peer-reviewed by experts, and includes practical articles, case studies, sustainability, etc.